STMC-103H has a combination of bacteria that are depleted in the gut microbiota of infants who go on to develop allergic sensitization and allergic diseases in childhood.
If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.